Posted on mongodb google news. Visit mongodb google news

Taysha’s focus is on its lead candidate TSHA-102, which incorporates a minMeCP2 transgene and self-regulatory element designed to restore expression levels without causing toxic overexpression. Early results from the Phase 1/2 REVEAL trials, which include both low-dose adult and pediatric cohorts, have shown promising safety and signs of efficacy.

The company’s immediate future involves a keen focus on the second half of 2024, when it anticipates safety and efficacy data for the high-dose cohort from the ongoing trials. This forthcoming data is crucial as it could further validate the therapeutic potential of TSHA-102 in treating Rett syndrome.

BMO Capital’s initiation of coverage with an Outperform rating reflects a positive outlook on Taysha’s approach to gene therapy and its capacity to meet a significant unmet need within the Rett syndrome treatment landscape. The $5.00 price target set by the firm indicates confidence in the company’s direction and the anticipated milestones ahead.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Article originally posted on mongodb google news. Visit mongodb google news